相关实验视频

Updated: Jul 26, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

一个可向的途径,以消除TRA-1-60+/TRA-1-81+耐化学性癌细胞

Lei Tan^1,2, Xiaohua Duan^1,3, Pratyusha Mutyala¹

¹Department of Surgery, Weill Cornell Medicine, New York, NY 10065, USA.

Journal of molecular cell biology

|June 16, 2023

概括

研究人员确定TRA-1-60和TRA-1-81是化学抵抗性胰腺癌细胞的关键细胞表面标记物. 用诸如 Cymarin 这样的化合物准这些标记物可能为克服治疗失败提供新的治疗策略.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
药物发现药物发现药物发现

背景情况:

化学抵抗显著限制了胰腺癌的治疗疗效.
识别化学耐药癌细胞 (CCC) 上的特定标记物对于开发向疗法至关重要.

研究的目的:

为了确定与胰腺癌中化学抵抗相关的新型细胞表面标记物.
阐明化学抵抗背后的分子机制.
发现潜在的治疗药物来克服化学抵抗.

主要方法:

基于抗体的查,以确定CCC上的细胞表面标记物.
转录组分析,以了解CCC中的基因表达.
高含量的化学选用于识别候选药物.
治疗剂的体外和体内验证.

主要成果:

在CCC上,TRA-1-60和TRA-1-81被确定为高度丰富的"干细胞"细胞表面标记物.
发现UGT1A10对于维持TRA-1-60/TRA-1-81表达和耐化学反应至关重要.
新型化合物西马林降低了UGT1A10,降低了TRA-1-60/TRA-1-81的表达,并增强了化学敏感性.
在原发性胰腺瘤中,TRA-1-60/TRA-1-81表达与化学抵抗和低生存率相关.

结论:

TRA-1-60/TRA-1-81 是一种新型的,针对化学抵抗性胰腺癌细胞的细胞表面特异标记物.
对于维持化学抗药性而言,UGT1A10通路至关重要.
奇玛林作为一种治疗剂,有望准这种途径并改善治疗结果.

关键词:

锡马林是一种.在TRA-1-60/TRA-1-81中,我们可以看到TRA-1-60,TRA-1-81.美国UGT1A10 化学电阻是一种化学电阻.胰腺癌是一种癌症.

更多相关视频

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...